Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences (Nasdaq: CSTL) said its executive management will present a company overview at the Stephens 27th Annual Investment Conference on Nov 19, 2025 at 10:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Castle Biosciences (Nasdaq: CSTL) said its executive management will present a company overview at the Stephens 27th Annual Investment Conference on Nov 19, 2025 at 10:00 a.m. ET. A live audio webcast will be available at the company’s investor website and a replay will be posted after the broadcast. Castle also will be available for one-on-one investor meetings at the Jefferies Global Healthcare Conference on Nov 18–20, 2025, with meetings requestable through Jefferies Financial Group.
Details
News Market Reaction – CSTL
On Oct 28, the day this news came out, CSTL closed 0.79% above the previous close.
Data tracked by StockTitan Argus for the Oct 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens 27th Annual Investment Conference on Wednesday, Nov. 19, 2025, at 10:00 a.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the Jefferies Global Healthcare Conference, being held Nov. 18-20, 2025. Meetings may be requested exclusively through Jefferies Financial Group.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide treatment decisions for patients with moderate-to-severe atopic dermatitis. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.